Table 1. Relationship between uPAR expression in bone marrow and peripheral blood and clinicopathologic findings.
uPAR expression in bone marrow
|
uPAR expression in peripheral blood
|
||||||
---|---|---|---|---|---|---|---|
Positive | Negative | Positive | Negative | ||||
Total | 846 | n=431 (50.9%) | n=415 (49.1%) | P-value | n=404 (47.8%) | n=442 (52.2%) | P-value |
Age (mean±s.d.a) | 60.4±0.55 | 62.7±0.56 | NS | 61.5±0.57 | 61.6±0.55 | NS | |
Gender | 0.233 | 0.688 | |||||
Male | 567 | 297 (69.1) | 270 (65.2) | 268 (66.5) | 299 (67.8) | ||
Female | 279 | 134 (30.9) | 145 (34.8) | 136 (33.5) | 143 (32.2) | ||
Histology | 0.127 | 0.174 | |||||
Differentiated | 188 | 105 (24.4) | 83 (20.0) | 98 (24.3) | 90 (20.4) | ||
Undifferentiated | 658 | 326 (75.6) | 332 (80.0) | 306 (75.7) | 352 (79.6) | ||
pT | 0.015 | 0.009 | |||||
pT1/T2 | 657 | 320 (74.3) | 337 (81.2) | 298 (73.8) | 359 (81.2) | ||
pT3/T4 | 189 | 111 (25.7) | 78 (18.8) | 106 (26.2) | 83 (18.8) | ||
pN | 0.707 | 0.072 | |||||
pN0 | 496 | 250 (58.0) | 246 (59.3) | 224 (55.5) | 272 (61.5) | ||
pN1 | 350 | 181 (42.0) | 169 (40.7) | 180 (44.5) | 170 (38.5) | ||
pM (Distant metastasisa) | 0.044 | 0.002 | |||||
pM0 | 743 | 369 (85.6) | 374 (90.1) | 340 (84.2) | 403 (91.2) | ||
pM1 | 103 | 62 (14.4) | 41 (9.9) | 64 (15.8) | 39 (8.8) | ||
Postoperative recurrence | 0.01 | 0.115 | |||||
Non recurrence | 833 | 420 (97.5) | 413 (99.5) | 395 (97.8) | 438 (99.1) | ||
Recurrence | 13 | 11 (2.5) | 2 (0.5) | 9 (2.2) | 4 (0.9) | ||
Lymphatic invasion | 0.617 | 0.16 | |||||
Negative | 486 | 244 (58.3) | 242 (58.3) | 222 (55.0) | 264 (59.7) | ||
Positive | 360 | 187 (56.6) | 173 (41.7) | 182 (45.0) | 178 (40.3) | ||
Venous invasion | 0.425 | 0.039 | |||||
Negative | 702 | 362 (83.9) | 340 (81.9) | 324 (80.2) | 378 (85.5) | ||
Positive | 144 | 69 (16.1) | 75 (18.1) | 80 (19.8) | 64 (14.5) | ||
Stage | 0.081 | 0.008 | |||||
I, II | 634 | 312 (72.4) | 322 (77.6) | 286 (70.8) | 348 (78.7) | ||
III, IV | 212 | 119 (27.6) | 93 (22.4) | 118 (29.2) | 94 (21.3) |
Gastric cancer case with liver (H1) and/or lung metastasis (M1), cytology positive of peritoneal washes (CY1), peritoneal dissemination (P), and lymph node metastasis in the distant region (N3).